The influences of Taiwan's generic grouping price policy on drug prices and expenditures: Evidence from analysing the consumption of the three most-used classes of cardiovascular drugs

Table 7 Reimbursement rate changes from the pre- to the post-action period

Beta blocking agents
Number of all kinds covered by the NHI in the pre- or the post-action period	170
Number of kinds with price reduction after the action	65
% of kinds with price reduction after the action	38.24%
The average level of price reduction (%) of those with reduced prices	16.67%
Calcium channel blockers, vascular effects
Number of all kinds covered by the NHI in the pre- or the post-action period	74
Number of kinds with price reduction after the action	48
% of kinds with price reduction after the action	64.86%
The average level of price reduction (%) of those with reduced prices	12.87%
ACE inhibitors, plain
Number of all kinds covered by the NHI in the pre- or the post-action period	95
Number of kinds with price reduction after the action	50
% of kinds with price reduction after the action	52.63%
The average level of price reduction (%) of those with reduced prices	11.36%

ISSN: 1471-2458